PACIRA BIOSCIENCES, INC. Payments of Stock Issuance Costs
PACIRA BIOSCIENCES, INC. (PCRX) reported Payments of Stock Issuance Costs of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2014-02-25
- PACIRA BIOSCIENCES, INC. payments of stock issuance costs for the quarter ending 2011-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. payments of stock issuance costs for the quarter ending 2011-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. payments of stock issuance costs for the quarter ending 2011-06-30 was $0.00.
- PACIRA BIOSCIENCES, INC. payments of stock issuance costs for the quarter ending 2011-03-31 was $907.00K.
- PACIRA BIOSCIENCES, INC. payments of stock issuance costs for fiscal 2013 was $0.00.
- PACIRA BIOSCIENCES, INC. payments of stock issuance costs for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- PACIRA BIOSCIENCES, INC. payments of stock issuance costs for fiscal 2011 was $907.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-25 | |||
| 2012-12-31 | $0.00 10-K · filed 2014-02-25 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $0.00 derived: sum of 2 quarters · filed 2014-02-25 | $0.00 derived: sum of 3 quarters · filed 2014-02-25 | $907.00K 10-K · filed 2014-02-25 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $0.00 derived: sum of 2 quarters · filed 2012-11-01 | $907.00K 10-Q · filed 2012-11-01 | |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $907.00K 10-Q · filed 2012-08-09 | ||
| 2011-03-31 | $907.00K 10-Q · filed 2012-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |